Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT06149559

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Conditions: Generalized Myasthenia Gravis

Sex: All

Ages: 2 Years – 17 Years

Healthy volunteers: No

Phase: PHASE2, PHASE3

Enrollment: 12

Sponsor: UCB Biopharma SRL

Location: Mg0006 50574 Denton Texas

Summary

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \

Eligibility Criteria

Inclusion Criteria: * Study participant must be ≥2 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06149559). StuddyBuddy aggregates publicly available trial information.